Title of article
Resistance to HER2-targeted therapy
Author/Authors
Valadan، Reza نويسنده Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Valadan, Reza , Rafiei، Alireza نويسنده , , Tehrani، Mohsen نويسنده Immunobiochemistry lab, Immunology Research Center, Bu-Ali Research Institute, Mashhad, Iran , , Nejatollahi، Forough نويسنده Recombinant antibody laboratory, Department of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Nejatollahi, Forough
Issue Information
فصلنامه با شماره پیاپی 1 سال 2013
Pages
9
From page
1
To page
9
Abstract
Production and approval of trastuzumab (Herceptin®) for the treatment of
metastatic breast cancer (MBC) was a millstone in antibody-based targeted
therapy in the cancer treatment. However, despite the early success in the clinical
trials, trastuzumab failed to appreciate the initial attraction due to development of
resistance to the drug. Majority of patients who benefit from the drug acquire
resistance to it and experience tumor recurrence within 1 year. Several molecular
and cellular mechanisms underlying the resistance to trastuzumab have been
proposed. In this review, first, we provide a brief history leading to production of
trastuzumab. Also we consider the cellular and molecular antitumor effects of
trastuzumab and then, we discuss the mechanisms underlying trastuzumab
resistance in four levels.
Journal title
Research in Molecular Medicine
Serial Year
2013
Journal title
Research in Molecular Medicine
Record number
1026324
Link To Document